Back to search

University of British Columbia

A concerted genomic and proteomic approach to understand the early stages of prostate carcinogenesis

Abstract

dc:description

Cancer of the prostate (CaP) is the most common cancer in men and the second leading cause of death from cancer. To improve survival rates, an understanding of the molecular events that govern this disease is critical. We approach this goal through a concerted effort to identify the critical, early genomic and proteomic changes that cause the transformation of normal cells into their pre- and cancerous stages. In the past however, these molecular studies were greatly hindered by the heterogeneity of the tissue and the small size of the early stage lesions. To overcome these problems, a protocol for microdissection of progressionspecific cells from sections of both paraffin-embedded and fresh frozen radical prostatectomy samples that would allow the extraction of high quantity and quality DNA was developed. Further, a standardized protocol for DNA quantitation tailored for these minute microdissected samples was established. Using these protocols, 75 radical prostatectomy specimens were studied. 28 of these specimens (totaling 28 normal, 15 PIN and 30 early invasive carcinoma - Gleason grades 2 to 4) yielded sufficient DNA of favorable quantity and quality for SMAL (Scanning of Microdissected Archival Lesions)-PCR fingerprinting. Polymorphic DNA fingerprint fragments correlated with early prostate cancer progression were identified and mapped to 1p32, 2p23, 3p26, 4q35, 5q23, 8q22, 8q24, 9q22, 11p13, 12p12-13, 16q12, 18q21. Regions of allelic imbalance were reviewed by literature analysis and candidate genes were proposed. As a complementary approach, a working protocol for the use of Laser Capture Microdissection (LCM) coupled with the SELDI ProteinChip™ was also developed and standardized. Using this protocol, a pilot experiment was then conducted by comparing SELDI generated protein profiles from lysates of microdissected normal and early tumor cells from 5 fresh frozen human prostatic specimens. A recurrent gain of a 24kDa protein peak in cancer was observed in 2 out of 5 patients. Groundwork has been laid for others to fine-map and defines the boundaries of the potential prostate cancer genes. Furthermore, using the same method in the proteomic approach, others can now screen more patients for similar protein alterations that may signal the initiation of a developing cancer.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Pathology
Grantor dc:publisher
University of British Columbia
Year dc:date
2003

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Ma, Stephanie

Rights

dc:rights
Statement dc:rights
  • For non-commercial purposes only, such as research, private study and education. Additional conditions apply, see Terms of Use https://open.library.ubc.ca/terms_of_use.
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/13967

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Ma, Stephanie. A concerted genomic and proteomic approach to understand the early stages of prostate carcinogenesis. master's thesis, University of British Columbia, 2003. http://hdl.handle.net/2429/13967